drugset / Trial / NCT00654875

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

NCT00654875

Phase 4 Completed 328 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Timeline

Start
2008-03
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg